Randomised Phase 2 study of maintenance linsitinib (OSI-906) in combination with erlotinib compared with placebo plus erlotinib after platinum-based chemotherapy in patients with advanced non-small cell lung cancer

Autor: Debbie Whitcomb, Jan M. Vantornout, Keunchil Park, Mike Thomas, Jihong Chen, Fiona H Blackhall, Samreen Ahmed, J. Mezger, Srinivasu Poondru, Joo Hang Kim, Tudor Ciuleanu

Publikováno v: Ciuleanu, TE, Ahmed, S, Kim, JH, Mezger, J, Park, K, Thomas, M, Chen, J, Poondru, S, VanTornout, JM, Whitcomb, D & Blackhall, F 2017, ' Randomised Phase 2 study of maintenance linsitinib (OSI-906) in combination with erlotinib compared with placebo plus erlotinib after platinum-based chemotherapy in patients with advanced non-small cell lung cancer ', British Journal of Cancer, vol. 117, pp. 757-766 . https://doi.org/10.1038/bjc.2017.226
British Journal of Cancer

BACKGROUND: Maintenance therapy is important in advanced/metastatic non-small cell lung cancer (NSCLC). Erlotinib as switch maintenance following platinum-based chemotherapy increases survival. Cross-talk between the epidermal growth factor receptor

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1641db469c39b78133a996734d718827
https://pure.manchester.ac.uk/ws/files/60197496/205_manuscript_submitted_to_BJC.pdf